News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Idera Pharmaceuticals, Inc. (IDRA) Announces Presentation of Preclinical Data of IMO-8400 in Both Lupus and Psoriasis Models


5/1/2012 11:06:31 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications. The data from the SLE model will be presented in an oral presentation at the American Association of Immunologists (AAI) meeting in Boston, Massachusetts at 8:00a.m. ET on May 5, 2012. The oral presentation, entitled “IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in lupus-prone NZBW/F1 mice,” will be made during the session “Therapeutic Strategies for Rheumatologic Diseases.”

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES